Table 2.
Patterns of failure
| Variable | Luminal A (n=113) | Luminal B1 (n=33) | Luminal B2 (n=83) | HER2 (T+) (n=14) | HER2 (T–) (n=31) | Triple negative (n=61) | Total (n=335) |
|---|---|---|---|---|---|---|---|
| Any recurrence | 16 (14.2) | 9 (27.3) | 21 (25.3) | 2 (14.3) | 9 (29.0) | 20 (32.8) | 77 (23.0) |
| LRR | 4 (3.5) | 3 (9.1) | 10 (12.0) | 1 (7.1) | 6 (19.4) | 13 (21.3) | 37 (11.0) |
| IBTR | 3 (2.7) | 3 (9.1) | 7 (8.4) | 1 (7.1) | 3 (9.7) | 9 (14.8) | 26 (7.8) |
| Regional recurrence | 1 (0.9) | 2 (6.1) | 3 (3.6) | 0 | 3 (9.7) | 6 (9.8) | 15 (4.5) |
| Axillary lymph node | 0 | 2 | 2 | 0 | 0 | 0 | 4 |
| SCLN | 0 | 0 | 0 | 0 | 2 | 3 | 5 |
| IMLN | 1 | 1 | 1 | 0 | 2 | 4 | 9 |
| Distant metastasis | 14 (12.4) | 8 (24.2) | 18 (21.7) | 2 (14.3) | 7 (22.6) | 18 (29.5) | 67 (20.0) |
Values are presented as number (%). HER2 (T+), HER2 with trastuzumab; HER2 (T–), HER2 without trastuzumab; LRR, locoregional recurrence; IBTR, ipsilateral breast tumor recurrence; SCLN, supraclavicular lymph node; IMLN, internal mammary lymph node.